We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use www.guysandstthomasevents.co.uk, remember your settings and improve our services. We also use cookies set by other sites to help us deliver content from their services.
Home–Courses–3rd Developments and Controversies in Thyroid Cancer 2024
3rd Developments and Controversies in Thyroid Cancer 2024
This symposium will provide an update on the management of recurrent primarily differentiated thyroid cancer by focusing on the understanding of the latest evidence
Thyroid cancer incidence continues to increase partly due to a significant number of incidental new findings of this disease. This has caused a noteworthy growth in the numbers of patients discussed and treated within thyroid cancer multidisciplinary teams.
After previously successful symposiums held on early and advanced thyroid cancer, this symposium will focus on the management of recurrent thyroid cancer. This area of practice has significantly evolved in the past few years but has also created a number of controversies primarily due to the lack of evidence in this field. This causes significant discussions within multidisciplinary teams dealing with these clinical scenarios and also in international forums.
Objectives
The aim of the symposium is to provide an update on the management of recurrent primarily differentiated thyroid cancer by focusing on the understanding of the latest evidence on:
Molecular and cellular predictors of recurrent thyroid cancer
Evaluation and work up of patients with recurrent thyroid cancer
Surgical approaches to recurrent thyroid cancer in the primary site, neck and distant sites
The use of non-surgical treatment for recurrent thyroid cancer
To understand the current evidence and controversies to support clinical practice decision making
Who should attend
The symposium is targeted to all members of the thyroid multidisciplinary teams treating thyroid cancer including qualified staff and trainees. These include Surgeons, Endocrinologists, Nuclear Physicians, Oncologists, Clinical Nurse Specialists, and Speech and Language Therapists.
